Personalized medicine

adyn Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023

Retrieved on: 
Thursday, March 2, 2023
Woman, NASA, Biology, Personalized medicine, Thrombus, Organization, Editorial, MrBeast, ITunes, Medicine, Diagnosis, Reproductive rights, Health, Genomics, Birth control

SEATTLE, March 02, 2023 (GLOBE NEWSWIRE) -- adyn has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.

Key Points: 
  • SEATTLE, March 02, 2023 (GLOBE NEWSWIRE) -- adyn has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
  • In addition to the World’s 50 Most Innovative Companies, 540 organizations are recognized across 54 sectors and regions.
  • The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year.
  • Fast Company’s Most Innovative Companies issue (March/April 2023) is available online here , as well as in-app form via iTunes, and on newsstands beginning March 14.

Chemotherapy Alters Immune Cell Landscape in Pancreatic Cancer

Retrieved on: 
Wednesday, March 1, 2023
Fibroblast, Memorial, Memorial Sloan Kettering Cancer Center, Immunotherapy, Doctor of Philosophy, NYU, Cancer, Tamas, TIGIT, Diagnosis, Pathology, Immune system, PDAC, Nature Communications, Virus, Research, NYU Langone Health, Patient, Perlmutter, Pancreatic tumor, Pancreas, New York University Grossman School of Medicine, Tumor microenvironment, Personalized medicine, Macrophage, Bangladesh Technical Education Board, Neoplasm, National Institutes of Health, Pharmaceutical industry, Vaccine, Medical imaging, MD, Medicine

NEW YORK, March 1, 2023 /PRNewswire/ -- Chemotherapy affects the ability of a patient's immune system to attack pancreatic tumors, a new study shows.

Key Points: 
  • NEW YORK, March 1, 2023 /PRNewswire/ -- Chemotherapy affects the ability of a patient's immune system to attack pancreatic tumors, a new study shows.
  • Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the work revolves around the immune system, which includes T cells designed to attack foreign organisms like viruses.
  • The body also recognizes tumors as abnormal, but cancer cells hijack checkpoints to turn off immune responses.
  • A prominent type of immunotherapy seeks to shut down checkpoints, thereby making cancer cells "visible" again to the immune system.

CAP Marks 10+ Years in Ensuring Quality NGS Testing

Retrieved on: 
Thursday, February 23, 2023
Research, Other Health, General Health, Technology, Infectious Diseases, Continuing, University, Health Technology, Education, Science, Biotechnology, Other Technology, Health, NGS, Clinical, American College, CAP, CDC, Pathology, AMP, Organization, PT, Partnership, American College of Medical Genetics and Genomics, FDA, CLSI, Guideline, Accreditation, Medical genetics, Korea Disease Control and Prevention Agency, ACMG, Exome, Personalized medicine, Food, Food and Drug Administration, Medical device, MD, Genomics

Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving quality of next-generation sequencing (NGS) testing through laboratory accreditation and proficiency testing (PT) programs.

Key Points: 
  • Precision medicine continues to gain momentum from the laboratory benchtop to the patient's bedside, with the CAP leading—as it has for over 10 years—in improving quality of next-generation sequencing (NGS) testing through laboratory accreditation and proficiency testing (PT) programs.
  • “The CAP was the first accrediting organization in the U.S. to publish accreditation requirements specific to NGS to address its emerging use in diagnostic testing,” explained CAP President Emily E. Volk, MD, FCAP, adding that over 10 years ago, the NGS requirements were published in the 2012 Edition of the CAP Molecular Pathology checklist.
  • The CAP is also working with the CDC to develop standards related to NGS testing.
  • CAP launched its first wet specimen NGS germline PT program in 2015; somatic solid tumor and hematologic NGS PT programs were added in 2016.

Allelica to perform breast cancer polygenic risk score study with Taiwanese biobanks

Retrieved on: 
Wednesday, February 22, 2023
Initiative, Federated, Woman, Laboratory, AUC, Personalized medicine, OR, Medicine, Cancer, PRS, Breast cancer, Patient, SD, WGS, Calibration, Genetics, Hasselt, Module, Coronary artery disease, Version 2.0, Whole genome sequencing, SP, Heart, Chronic kidney disease, Conditional sentence, Cardiovascular disease, Birth control, Pharmaceutical industry

NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Allelica, the leading provider of polygenic risk score analysis technology, announced that it has joined forces with the Taiwanese precision medicine provider, SP BioMED, to perform a polygenic risk score (PRS) study for breast cancer. SP BioMED will run PRS analysis using Allelica's PREDICT module to calculate PRS for breast cancer on known breast cancer cases in their local biobanks.

Key Points: 
  • NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Allelica, the leading provider of polygenic risk score analysis technology, announced that it has joined forces with the Taiwanese precision medicine provider, SP BioMED, to perform a polygenic risk score (PRS) study for breast cancer.
  • SP BioMED will run PRS analysis using Allelica's PREDICT module to calculate PRS for breast cancer on known breast cancer cases in their local biobanks.
  • "Breast cancer is the most common cause of cancer in Taiwanese women, so understanding the role that genetics plays in this disease risk is critical to identifying women at high risk," said Allelica CSO, George Busby.
  • The breast cancer PRS calculated in the study is Allelica's proprietary PRS for breast cancer which has been clinically validated in multiple ancestries.

PathAI Announces Two New Executives to Expand Regulatory Expertise and Precision Oncology Commercial Strategy

Retrieved on: 
Thursday, February 16, 2023
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, Foundation Medicine, Medicine, Personalized medicine, Regulatory affairs, NGS, FDA Center for Devices and Radiological Health, Food, European Medicines Agency, Pathology, Sutro Biopharma, Knowledge, FDA, Growth, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AstraZeneca, Medical device

These new leaders will build on the company’s position at the forefront of AI-driven pathology and will advance its growth in the precision diagnostics market with their regulatory and commercial expertise.

Key Points: 
  • These new leaders will build on the company’s position at the forefront of AI-driven pathology and will advance its growth in the precision diagnostics market with their regulatory and commercial expertise.
  • With deep experience in regulatory and strategic issues across the precision medicine field, Dr. Madison brings strong cross-functional expertise to PathAI, with a focus on the development of oncology products, both diagnostic and therapeutic.
  • Madison brings exceptional talent to PathAI, combining knowledge in precision oncology and companion diagnostics, an understanding of the regulatory requirements for innovative diagnostics, and therapeutic development experience,” said Nick Brown, Chief Commercial Officer for Biopharma and Digital Diagnostics at PathAI.
  • Madison will help propel PathAI forward in the oncology space by refining our companion diagnostic strategy and broader offerings to oncology developers.”

Global Induced Pluripotent Stem Cell (iPSC) Industry Report 2023: Profiles Leading Market Competitors, Including FUJIFILM CDI, ReproCELL, Evotec, Ncardia, and Axol Bioscience - ResearchAndMarkets.com

Retrieved on: 
Monday, February 13, 2023
Health, Stem Cells, Macular degeneration, Regenerative medicine, Cellular Dynamics International, B cell, Toxicology, Game Industry Report Magazine, Human, Thermo Fisher Scientific, Drug development, Therapy, IPSC, Medicine, Cell, 3D bioprinting, Safety, University of Wisconsin–Madison, Patient, CRISPR, Clinical trial, CLI, University, CDI, Research, MSC, Tissue engineering, Merck, Graft-versus-host disease, Kyoto University, Personalized medicine, Disease, Partnership, OA, COVID-19, Drug discovery, Microsoft Exchange Server, Osteoarthritis, Pharmaceutical industry, Veterinary medicine, Mobile phone, Fine chemical

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2023" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Personalized Medicine:The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single base changes) in many cell types.
  • Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

Majority of Cambridge Research Papers Now Open Access

Retrieved on: 
Monday, February 6, 2023
Education, Communications, Research, Publishing, Science, University, Climate, ChemRxiv, Personalized medicine, Assessment, Cambridge University Press & Assessment, Publication, Cambridge University Press, Medicine, Plastic, American Political Science Association, Water, University of Cambridge, APSA, Student, Humanities, Map, Partnership, OA, Social, Book, Pharmaceutical industry, Management

Having passed the 50 percent threshold for last year – approximately 10,000 papers being fully open – Cambridge University Press is aiming for the vast majority of its research papers to be published fully open access by 2025.

Key Points: 
  • Having passed the 50 percent threshold for last year – approximately 10,000 papers being fully open – Cambridge University Press is aiming for the vast majority of its research papers to be published fully open access by 2025.
  • Cambridge hitting this open access milestone is especially remarkable, as about 60 percent of its research publications are in the humanities and social sciences - fields where research funding constraints have historically held back open research adoption, relative to science, technology and medicine.
  • Over 400 Cambridge journals offer open access options to publishers; 66 with fully open access and 340 hybrid.
  • “That’s why we will not stop at half of our journal papers being open access: we are working to make the vast majority of such research fully open by 2025.

Weill Cornell Medicine and NanoString Collaborate to Create Comprehensive Spatial Atlas of Human Anatomy

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Health, Genetics, Science, Research, SAHA, Pathology, DSP, Personalized medicine, Protein, RNA, SVP, SMI, Data analysis, Organelle, Medical laboratory, Physiology, CSO, DRS, Transcriptome, Weill Cornell Medicine, John J. Carty Award for the Advancement of Science, NanoString Technologies, Human body, Medical imaging, Microscope, Biophysics

The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.

Key Points: 
  • The goal is to create a comprehensive open source, spatial reference standard that can be accessed by researchers around the globe to advance our knowledge of spatial biology.
  • “The goal is for SAHA to be a foundational database that can serve as a benchmark reference for spatial precision medicine.
  • Comparing spatial datasets of various organs from multiple ethnicities can capture the variability in samples that researchers do not currently understand,” stated Chris Mason, Professor of Physiology and Biophysics, Weill Cornell Medicine.
  • SAHA is a collaborative effort with Weill Cornell Medicine’s Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, and the WorldQuant Initiative for Quantitative Prediction.

The Worldwide Consumer Genomics Industry is Expected to Reach $9 Billion by 2027: Increase in Access to DTC Services due to Reducing the Cost of Genotyping Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Other Health, Men, Family, Consumer, Medical Devices, Genetics, Science, Women, Biotechnology, Medical Supplies, Other Science, Health, Co-production (public services), Investment, Emotion, Ansoff matrix, COVID-19, Market development, Geography, Porter's five forces analysis, Impact, System, SWOT, Risk, Diagnosis, USD, Consumables, Personalized medicine, Growth, Observation, Ancestor, Retail, Risk management, Medical device, Application

These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.

Key Points: 
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the Global Consumer Genomics Market.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
  • The report offers a comprehensive evaluation of the Global Consumer Genomics Market.

IQHQ Appoints Janice Sears and Anshul Mangal as Independent Members to its Board of Directors

Retrieved on: 
Monday, January 23, 2023
Health, Commercial Building & Real Estate, Construction & Property, General Health, REIT, Biotechnology, Electricity, University of Illinois Chicago School of Law, Purdue University, Chemical Bank, Retirement, Personalized medicine, United Kingdom, Refugee, Commercial, Jones, Marketing, NYSE, Patient, Real estate, Jones Day, University of Illinois Chicago School of Public Health, University, Computer, Bank of America, Chicago-Kent College of Law, Bank, Citigroup, Sears, Invitation Homes, Management, Science, Economics

IQHQ, Inc., a premier life sciences real estate development company, today announced key additions to its Board of Directors – naming Janice Sears and Anshul Mangal as independent directors.

Key Points: 
  • IQHQ, Inc., a premier life sciences real estate development company, today announced key additions to its Board of Directors – naming Janice Sears and Anshul Mangal as independent directors.
  • “We are pleased to add Janice and Anshul to our esteemed Board of Directors,” said Steve Rosetta, CEO of IQHQ.
  • “Janice brings an unparalleled track record of financial, investor, and commercial real estate expertise, which will play a critical role in our future growth plans.
  • “I am excited to join the IQHQ Board of Directors and use my expertise to further the development of IQHQ’s portfolio,” said Mangal.